Show simple item record

dc.contributor.authorTostmann, A
dc.contributor.authorBoeree, M J
dc.contributor.authorHarries, A D
dc.contributor.authorSauvageot, D
dc.contributor.authorBanda, H T
dc.contributor.authorZijlstra, E E
dc.date.accessioned2008-02-14T11:00:46Z
dc.date.available2008-02-14T11:00:46Z
dc.date.issued2007-07
dc.identifier.citationShort communication: antituberculosis drug-induced hepatotoxicity is unexpectedly low in HIV-infected pulmonary tuberculosis patients in Malawi. 2007, 12 (7):852-5 Trop. Med. Int. Health
dc.identifier.issn1360-2276
dc.identifier.pmid17596252
dc.identifier.doi10.1111/j.1365-3156.2007.01871.x
dc.identifier.urihttp://hdl.handle.net/10144/18241
dc.description.abstractThe proportion of patients with antituberculosis drug-induced hepatotoxicity (ATDH) was unexpectedly low during a trial on cotrimoxazole prophylaxis in Malawian HIV-positive pulmonary tuberculosis patients. About 2% of the patients developed grade 2 or 3 hepatotoxicity during tuberculosis (TB) treatment, according to WHO definitions. Data on ATDH in sub-Saharan Africa are limited. Although the numbers are not very strong, our trial and other papers suggest that ATDH is uncommon in this region. These findings are encouraging in that hepatotoxicity may cause less problem than expected, especially in the light of combined HIV/TB treatment, where drug toxicity is a major cause of treatment interruption.
dc.language.isoen
dc.relation.urlhttp://www.blackwell-synergy.com/loi/tmi
dc.rightsArchived on this site with the kind permission of Wiley-Blackwellen_GB
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAge Distribution
dc.subject.meshAnti-Infective Agents
dc.subject.meshAntitubercular Agents
dc.subject.meshDrug Administration Schedule
dc.subject.meshFemale
dc.subject.meshHIV Infections
dc.subject.meshHumans
dc.subject.meshLiver Diseases
dc.subject.meshMalawi
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshSex Distribution
dc.subject.meshTrimethoprim-Sulfamethoxazole Combination
dc.subject.meshTuberculosis, Pulmonary
dc.titleShort communication: antituberculosis drug-induced hepatotoxicity is unexpectedly low in HIV-infected pulmonary tuberculosis patients in Malawi.
dc.contributor.departmentDepartment of Pulmonary Diseases, Radboud University Nijmegen Medical Centre and University Lung Centre Dekkerswald, Nijmegen, The Netherlands. A.Tostmann@ulc.umcn.nl
dc.identifier.journalTropical Medicine & International Health
refterms.dateFOA2019-03-04T09:17:12Z
html.description.abstractThe proportion of patients with antituberculosis drug-induced hepatotoxicity (ATDH) was unexpectedly low during a trial on cotrimoxazole prophylaxis in Malawian HIV-positive pulmonary tuberculosis patients. About 2% of the patients developed grade 2 or 3 hepatotoxicity during tuberculosis (TB) treatment, according to WHO definitions. Data on ATDH in sub-Saharan Africa are limited. Although the numbers are not very strong, our trial and other papers suggest that ATDH is uncommon in this region. These findings are encouraging in that hepatotoxicity may cause less problem than expected, especially in the light of combined HIV/TB treatment, where drug toxicity is a major cause of treatment interruption.


Files in this item

Thumbnail
Name:
TBHIV.pdf
Size:
476.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record